Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Le poids des maladies cardiovasculaires

24 septembre 2026 mis à jour par: Kyla M. Lara-Breitinger, Mayo Clinic

Le poids des maladies cardiovasculaires : une étude pilote prospective sur des adultes obèses atteints de maladies cardiovasculaires évaluée dans une nouvelle clinique cardiométabolique

The purpose of this study is to evaluate the impact of a cardiometabolic clinic on percent body weight loss, body mass index (BMI), and visceral adiposity distribution in obese adults with cardiovascular disease (CVD) at 12 months.

Aperçu de l'étude

Statut

Actif, ne recrute pas

Type d'étude

Observationnel

Inscription (Réel)

31

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Minnesota
      • Rochester, Minnesota, États-Unis, 55905
        • Mayo Clinic in Rochester

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Patients referred to the cardiometabolic clinic at Mayo Clinic Hospital in Rochester, MN will be recruited for participation.

La description

Inclusion Criteria:

  • BMI ≥30 kg/m2
  • At least one of the following CVD: atrial fibrillation (AF), coronary artery disease (CAD), HFpEF (heart failure with preserved ejection fraction), HFrEF (heart failure with reduced ejection fraction), ACHD (adult congenital heart disease), or valvular heart disease
  • Patients evaluated in the Cardiometabolic clinic
  • Willingness to complete questionnaires/surveys
  • Ability to complete monthly self-assessments at home

Exclusion Criteria:

  • BMI <30 kg/m2
  • Pregnancy or lactating women
  • Hemodynamically unstable CVD
  • Active malignancy
  • Autoimmune or systemic inflammatory diseases
  • Severe renal or hepatic failure
  • Being considered unsafe to participate as determined by the study physician
  • Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic medications, or other medications as determined by the study NP or physician
  • Patients with active psychosis, mania, or substance use disorders

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percent body weight loss
Délai: 12 months

Total percent body weight loss will be reported at 12 months based on the following formula: (Starting baseline weight minus current weight) / (starting baseline weight) x 100 equals % of body weight loss.

12 months
Change in Body Mass Index (BMI)
Délai: Baseline, 12 months

Body Mass Index (BMI) will be calculated using the standard formula from participants' height and weight. BMI = (Weight in Pounds / (Height in inches x Height in inches)) x 703

Baseline, 12 months
Change in visceral adiposity distribution
Délai: Baseline, 12 months

Change in visceral adiposity distribution measured using dual energy X-ray absorptiometry (DEXA).

Baseline, 12 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in Blood Pressure
Délai: Baseline, 12 months

Measured in millimeters of mercury (mmHg)

Baseline, 12 months
Change in point of care glucose
Délai: Baseline, 12 months

Change in estimated glucose value (mg/dl) obtained from point of care fingerstick testing.

Baseline, 12 months
Change in quality of diet
Délai: Baseline, 12 months

Change in quality of diet will be assessed by the Mini-EAT (Eating Assessment Tool). The Mini-EAT is a 9 item questionnaire that asks subjects how often they eat different types of foods (e.g. fruits, vegetables, legumes, etc.). Subjects respond on a scale of "I do not eat it at all" to "6 or more servings per day." Higher scores on the Mini-EAT represent a better quality of diet.

Baseline, 12 months
Change in psychosocial distress as measured by Screening Tool for Psychological Distress (STOP-D)
Délai: Baseline, 12 months

Psychosocial distress will be measured by the STOP-D survey. The STOP-D survey asks subjects to rate how often over the last 2 weeks they have felt depressed, anxious, stressed, angry, or lacking social support on a scale of 0-Not at all to 9-Severely. Each item is scored separately without a summed score for overall distress. Higher individual scores on the STOP-D items represent worse psychosocial distress.

Baseline, 12 months
Change in psychosocial distress as measured by Impact of Event Scale-Revised (IES-R)
Délai: Baseline, 12 months

Psychosocial distress will be measured by the IES-R. The IES-R is a questionnaire which asks subjects to rate how distressed or bothered during the past seven days they have been by difficulties that people sometimes have after stressful life events. Responses can range from 0-Not at all to 4-Extremely. Items on the questionnaire are grouped into 3 subscales: Intrusion, Avoidance, and Hyperarousal with scores on each subscale being the mean item response of all items in that group, thus scores for each subscale also range from 0 to 4. Higher scores are indicative of more psychosocial distress following the specific life event of focus.

Baseline, 12 months
Change in psychosocial distress as measured by Adverse Childhood Experience (ACE) Questionnaire
Délai: Baseline, 12 months

Psychosocial distress will be measured by the ACE Questionnaire. The ACE Questionnaire asks subjects various questions regarding life experiences from the first 18 years of life that may be considered adverse experiences (e.g. parental abuse, neglect, parental divorce, etc.). Subjects answer each question with a yes or no selection. The more questions answered yes represents worse psychosocial distress.

Baseline, 12 months
Change in functional aerobic capacity (VO2 Max)
Délai: Baseline, 12 months

VO2 Max is measured as milliliters of oxygen per kilogram of body weight per minute (ml/kg/min) during cardiopulmonary exercise test

Baseline, 12 months
Change in artificial intelligence electrocardiogram (AI-ECG) age
Délai: Baseline, 12 months

AI-ECG age is the subject's predicted age based on artificial intelligence analysis of electrocardiograms (ECGs).

Baseline, 12 months
Change in E/e'
Délai: Baseline, 12 months

E/e' will be measured using transthoracic echocardiography (TTE). It is defined as the ratio of peak early diastolic mitral inflow velocity (E) and peak early diastolic mitral annular velocity (e') and will be used to assess left ventricular diastolic function.

Baseline, 12 months
Change in Peak Tricuspid Regurgitation (TR) Velocity
Délai: Baseline, 12 months

Peak TR Velocity (m/s) will be measured using transthoracic echocardiography (TTE) to assess left ventricular diastolic function.

Baseline, 12 months
Change in Right Atrial (RA) Pressure
Délai: Baseline, 12 months

RA pressure (mm Hg) will be measured by transthoracic echocardiography (TTE) to assess left ventricular diastolic function.

Baseline, 12 months
Change in Left Atrial (LA) volume index
Délai: Baseline, 12 months

LA volume index (ml/m^2) will be measured by transthoracic echocardiography (TTE) to assess left ventricular diastolic function.

Baseline, 12 months
Change in physical activity
Délai: Baseline, 12 months

Average number of steps a subject takes daily as collected by an Apple watch worn by subjects for the duration of the study.

Baseline, 12 months
Change in heart rate with detection of arrhythmia
Délai: Baseline, 12 months

Average number of arrhythmias identified by an Apple watch worn by subjects for the duration of the study.

Baseline, 12 months
Change in cardio fitness
Délai: Baseline, 12 months

Fitness level reported as high/above average/below average/low as collected by an Apple watch worn by subjects for the duration of the study.

Baseline, 12 months
Change in six-minute walk test
Délai: Baseline, 12 months

Measurement (meters) of distance a person can walk on flat ground in 6 minutes collected by an Apple watch worn by subjects for the duration of the study.

Baseline, 12 months
Change in psychosocial distress as measured by the Weight Bias Internalization-Modified (WBIS-M) scale
Délai: Baseline, 12 months

The WBIS-M is a 11-item instrument for measuring the extent to which overweight individuals think of themselves in terms of prevalent negative stereotypes about overweight and overweight individuals. Respondents can express their level of agreement on a 7-point Likert scale ranging from 'strongly disagree' (1) to 'strongly agree' (7). Items 1 and 9 need to be scored reversely. Scores are averaged to create a composite score and higher scores represent greater psychosocial distress.

Baseline, 12 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Kyla Lara-Breitinger, M.D., Mayo Clinic

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

22 avril 2024

Achèvement primaire (Estimé)

1 mai 2027

Achèvement de l'étude (Estimé)

1 mai 2027

Dates d'inscription aux études

Première soumission

19 septembre 2023

Première soumission répondant aux critères de contrôle qualité

19 septembre 2023

Première publication (Réel)

26 septembre 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

28 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

24 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner